$1.05
8.70% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
NL0012661870
Symbol
IFRX
Sector
Industry

InflaRx N.V. Stock price

$1.05
-0.20 16.00% 1M
-0.51 32.69% 6M
-1.42 57.49% YTD
-0.50 32.26% 1Y
-0.74 41.34% 3Y
-4.61 81.45% 5Y
-13.94 93.00% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.10 8.70%
ISIN
NL0012661870
Symbol
IFRX
Sector
Industry

Key metrics

Market capitalization $70.49m
Enterprise Value $6.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 38.22
P/S ratio (TTM) P/S ratio 391.61
P/B ratio (TTM) P/B ratio 0.85
Revenue growth (TTM) Revenue growth 178.84%
Revenue (TTM) Revenue $180.00k
EBIT (operating result TTM) EBIT $-61.24m
Free Cash Flow (TTM) Free Cash Flow $-51.68m
Cash position $64.61m
EPS (TTM) EPS $-1.05
P/E forward negative
P/S forward 117.26
EV/Sales forward 20.64
Short interest 0.92%
Show more

Is InflaRx N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

InflaRx N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a InflaRx N.V. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a InflaRx N.V. forecast:

Buy
83%
Hold
17%

Financial data from InflaRx N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
0.18 0.18
157% 157%
100%
- Direct Costs 1.03 1.03
14% 14%
572%
-0.84 -0.84
1% 1%
-467%
- Selling and Administrative Expenses 20 20
39% 39%
11,239%
- Research and Development Expense 40 40
10% 10%
22,011%
-61 -61
2% 2%
-33,717%
- Depreciation and Amortization 0.55 0.55
29% 29%
306%
EBIT (Operating Income) EBIT -61 -61
2% 2%
-34,025%
Net Profit -62 -62
66% 66%
-34,272%

In millions USD.

Don't miss a Thing! We will send you all news about InflaRx N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

InflaRx N.V. Stock News

Neutral
GlobeNewsWire
15 days ago
JENA, Germany, March 20, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the year ended December 31, 2024, highlighting recent operational achievements and expected milestones for 2025.
Neutral
GlobeNewsWire
27 days ago
JENA, Germany, March 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and ph...
Neutral
GlobeNewsWire
about one month ago
JENA, Germany, Feb. 28, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced acceptance of all submitted abstracts, featuring the role of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), to be presented during the 2025 American Academy of Dermatology...
More InflaRx N.V. News

Company Profile

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a. Its products includes IFX-1 and IFX-2. The company was founded by Niels Christoph Riedemann, Renfeng Guo and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany.

Head office Netherlands
CEO Niels Riedemann
Employees 74
Founded 2007
Website www.inflarx.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today